» Articles » PMID: 22633195

Serum Level of Interleukin-6 in Chinese Patients with Multiple Sclerosis

Overview
Journal J Neuroimmunol
Specialty Neurology
Date 2012 May 29
PMID 22633195
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to investigate the serum concentration of interleukin (IL)-6 in patients with relapsing-remitting MS (RR-MS), compare the difference between males and females, and explore the correlation between the serum concentration of IL-6 and clinical parameters like the current age, the age at onset, disease duration, disability (expanded disability status scale, EDSS), and the number of relapse. We compared the serum concentration of IL-6 in 39 patients with MS and 39 healthy controls matched with sex and age. The serum IL-6 concentration was measured by FlowCytomix. Compared to healthy controls, both the frequency of subjects with detectable level of IL-6 (P=0.005) and the serum concentration of IL-6 (P=0.004) were significantly higher in MS patients. When data were analyzed by gender, statistical significances between MS patients and healthy controls were observed only in females, although the frequency with detectable level and the serum concentration of IL-6 were higher in male MS patients than male controls. The serum level of IL-6 was found to be significantly positively correlated with the number of relapse for female MS patients (r(s)=0.511, P=0.009), with the current age for male MS patients (r(s)=0.700, P=0.005), and with the age at onset for all MS patients (r(s)=0.351, P=0.028). Our results may support that IL-6 is involved in the pathogenesis of MS and indicate that differences exist between male and female patients.

Citing Articles

Multiple Sclerosis: From the Application of Oligoclonal Bands to Novel Potential Biomarkers.

Maglio G, DAgostino M, Caronte F, Pezone L, Casamassimi A, Rienzo M Int J Mol Sci. 2024; 25(10).

PMID: 38791450 PMC: 11121866. DOI: 10.3390/ijms25105412.


Profiling blood-based brain biomarkers and cytokines in experimental autoimmune encephalomyelitis model of multiple sclerosis using single-molecule array technology.

Zahoor I, Mir S, Giri S bioRxiv. 2024; .

PMID: 38234812 PMC: 10793409. DOI: 10.1101/2023.12.25.573285.


Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials.

Schilke E, Remoli G, Funelli E, Galimberti M, Fusco M, Cereda D Neurol Sci. 2023; 45(5):1931-1944.

PMID: 38117403 PMC: 11021285. DOI: 10.1007/s10072-023-07228-3.


Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases.

Jiao L, Guo S Front Immunol. 2022; 13:966766.

PMID: 36389702 PMC: 9647084. DOI: 10.3389/fimmu.2022.966766.


A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis.

Barizzone N, Leone M, Pizzino A, Kockum I, Martinelli-Boneschi F, DAlfonso S J Pers Med. 2022; 12(9).

PMID: 36143216 PMC: 9501898. DOI: 10.3390/jpm12091430.